Clinical trials: IBD (Inflammatory Bowel Disease)
Crohn Disease
Trial Evaluating the Diagnostic Usefulness of Lumentin® 44 When Used as Contrast Agent
The trial is a phase 2 randomised, open, non-inferiority within patient-controlled multi-centre trial. Male and female subjects with a diagnosis of Crohn´s Disease and a clinical indication for an MRE examination, who are at…
- Trial name
- NCT04321941
- Testing
- Lumentin, Movprep
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Lument AB
Crohn's Disease
Immune Response Regulation and Nutritional Status of the Crohn's Disease Patients.
The objective of this study was to evaluate the effect of Whey Protein (WP) and Soy Protein (SP) nutritional supplements on nutritional status and disease activity in Crohn's disease patients.
- Trial name
- NCT01957423
- Testing
- Whey protein, Soy protein
- Where
- Brazil
- Volunteers
- 41 people
- Sponsor
- University of Campinas, Brazil
Crohns Disease
A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Crohn Disease on Advanced Therapies
Advanced therapies including biologics and small molecules target specific inflammatory pathways. IBD's multifactorial etiology means that blocking a single pathway may not be sufficient for all patients.
- Trial name
- BOOST-CD (NCT06890637)
- Testing
- Fecal Microbial Transplantation, Crohns Disease Exclusion Diet, Advanced therapy
- Where
- 6 sites in India
- Volunteers
- 168 people
- Sponsor
- All India Institute of Medical Sciences
Crohn Disease
Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Moderate and Severe Crohn's Disease
This is a prospective, single-arm, open-ended study to evaluate the efficacy and safety of human umbilical cord MSCs in the treatment of refractory moderate-to-severe Crohn's disease.
- Trial name
- NCT05262829
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai East Hospital
Colitis, Ulcerative
A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M
IBD98-M-2002 is a phase 2a , Randomized, Double blind, Placebo-controlled of IBD98-M Delayed Release capsules in subjects with Mild to Moderately Ulcerative Colitis to investigate the clinical efficacy of IBD98-M delayed release…
- Trial name
- NCT02493712
- Testing
- High dose, Low dose
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Crohn's Disease
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission…
- Trial name
- GEMINI II (NCT00783692)
- Testing
- vedolizumab
- Where
- 114 sites in United States, Canada and 1 more
- Volunteers
- 1,116 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Ulcerative Colitis (UC), Steatotic Liver Disease
Ulcerative Colitis Permeability
Study aim: To investigate whether the values of zonulin and lipopolysaccharide-binding protein (LBP) as biomarkers of intestinal permeability are related to the degree of liver steatosis, steatohepatitis and fibrosis in patients…
- Conditions
- Ulcerative Colitis (UC), Steatotic Liver Disease, Intestinal Permeability
- Trial name
- UCP (NCT07662902)
- Where
- Croatia
- Volunteers
- 100 people
- Sponsor
- University Hospital Dubrava
Inflammatory Bowel Diseases, Ulcerative Colitis
Evolution and Treatments of Chronic Inflammatory Systemic Diseases
Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, Arthritis, Rheumatoid
- Trial name
- MISTIC (NCT04191395)
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Ulcerative Colitis
Development and Validation of a Deep Learning Algorithm to Evaluate Endoscopic Disease Activity of Ulcerative Colitis.
The purpose of this study is to develop an artificial intelligence(AI) assisted scoring system, which can evaluate the disease severity and mucosal healing stage in patients with ulcerative colitis.
- Trial name
- NCT03973437
- Testing
- Artificial inteligence associated ulcerative colitis severity scoring system, Conventional human scoring
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shandong University
Crohn's Disease, Ulcerative Colitis
Evaluation of Molecular Mechanisms of Non-response to Therapy in Patients With Inflammatory Bowel Disease
Inflammatory bowel diseases (IBD) represent a group of immune-mediated disorders, in which currently unidentified trigger factors drive the manifestation of chronic relapsing- remitting destructive inflammatory episodes in the…
- Trial name
- 3TR (NCT05733845)
- Testing
- Samples
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Crohn Disease
A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease
This is a multicenter, Phase 3, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of etrolizumab compared with placebo during induction and maintenance treatment of moderately to severely…
- Trial name
- BERGAMOT (NCT02394028)
- Testing
- Etrolizumab
- Where
- 327 sites in United States, Argentina and 31 more
- Volunteers
- 1,035 people
- Sponsor
- Hoffmann-La Roche
Inflammatory Bowel Diseases
Clinnova-IBD, a Prospective Cohort of Patients With Inflammatory Bowel Disease (IBD)
This study is part of the Clinnova program. This is a prospective cohort study including patients with IBD recruited at the time of a treatment change.
- Trial name
- Clinnova-IBD (NCT05733702)
- Testing
- All participants will be asked to provide data and samples for collection and analysis.
- Where
- Luxembourg
- Volunteers
- 100 people
- Sponsor
- Luxembourg Institute of Health
Inflammatory Bowel Diseases, Crohn Disease
Implementing a Multimodal RCT Intervention to Improve the Transition of Patients With Crohn's Disease From Pediatric to Adult Care
Background: Transition in care is defined as the "purposeful and planned movement of adolescents and young adults with a chronic medical condition from pediatric to adult-oriented healthcare systems/care providers." Currently…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Adolescent Development
- Trial name
- NCT05221281
- Testing
- Multimodal intervention consisting of four core components, Standard of care
- Where
- 3 sites in Canada
- Volunteers
- 90 people
- Sponsor
- The Hospital for Sick Children
Ulcerative Colitis
ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.
This is a multi-center trial in the US and Europe to test the safety, efficacy and tolerability of alicaforsen (ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate active Ulcerative Colitis…
- Trial name
- NCT00063830
- Testing
- Alicaforsen
- Where
- United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Ulcerative Colitis
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
There are fewer therapeutic options for patients with active ulcerative colitis (UC) compared to patients with active Crohn's disease (CD) and the investigators are facing a persistent unmet need for additional effective and…
- Trial name
- Merit-UC (NCT01393405)
- Testing
- Methotrexate
- Where
- 31 sites in United States
- Volunteers
- 179 people
- Sponsor
- University of North Carolina, Chapel Hill
Ulcerative Colitis
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
This Phase III, double-blind, placebo and active-comparator controlled, multicenter study will investigate the efficacy and safety of etrolizumab in induction of remission in participants with moderately to severely active…
- Trial name
- HIBISCUS II (NCT02171429)
- Testing
- Adalimumab, Etrolizumab
- Where
- 90 sites in United States, Argentina and 17 more
- Volunteers
- 358 people
- Sponsor
- Hoffmann-La Roche
IBD (Inflammatory Bowel Disease), IBS (Irritable Bowel Syndrome)
Prevalence of Disorders of Gut-Brain-Interaction in Pediatric Patients With In-remission Inflammatory Bowel Disease
The medical management of inflammatory bowel disease (IBD) has evolved over the years thanks to the newly available therapies and the biochemical and endoscopic monitoring of the disease.
- Trial name
- IBD_IBS (NCT07539077)
- Testing
- DGBI prevalence
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pyoderma Gangrenosum, Crohn's Disease
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication.
- Conditions
- Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
- Trial name
- NCT00791557
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University Hospitals Cleveland Medical Center
IBD (Inflammatory Bowel Disease), Musculoskeletal Ultrasound
Utilization of Musculoskeletal Ultrasound to Detect Subclinical Findings in IBD Patients
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, frequently presents with musculoskeletal extraintestinal manifestations (EIMs), such as arthritis and enthesitis, affecting up to 50% of…
- Trial name
- NCT07205549
- Testing
- MSK Ultrasound with Doppler on joints, muscles & tendons
- Volunteers
- 81 people
- Sponsor
- Assiut University
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC).
- Conditions
- Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
- Trial name
- EMERALD-3 (NCT07415044)
- Testing
- LY4268989
- Where
- 258 sites in United States, Argentina and 26 more
- Volunteers
- 1,431 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.